The design, patient population and outcomes from the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registries

M M Brooks; K M Detre

doi:10.1006/siic.1999.0100

The design, patient population and outcomes from the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registries

Semin Interv Cardiol. 1999 Dec;4(4):191-9. doi: 10.1006/siic.1999.0100.

Authors

M M Brooks¹, K M Detre

Affiliation

¹ The Epidemiology Data Center, University of Pittsburgh, PA 15261, USA.

PMID: 10738352
DOI: 10.1006/siic.1999.0100

Abstract

The Bypass Angioplasty Revascularization Investigation (BARI) was designed to compare CAGB and PTCA for patients with symptomatic multivessel coronary artery disease. The randomized trial reported significant differences in 7-year survival favouring CABG. However, for the 353 patients with treated diabetes mellitus, an overwhelming benefit associated with CABG was seen (mortality: 23.6% CABG vs 44. 3% PTCA, p=0.0011), whilst no treatment difference was observed for the 1476 non-diabetic patients (13.6% CABG vs 13.2% PTCA, p=0.72). Patients assigned to PTCA experienced fewer in-hospital Q-wave MIs, but these patients received more revascularization procedures and more often had angina during follow-up.

Publication types

Clinical Trial
Comparative Study
Controlled Clinical Trial

MeSH terms

Angioplasty, Balloon, Coronary*
Coronary Artery Bypass*
Coronary Disease / surgery
Coronary Disease / therapy*
Diabetic Angiopathies / therapy
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Registries
Research Design
Treatment Outcome